• Sernova Biotherapeutics agreed to combine with Seraxis to form BetaNova Biotherapeutics, a U.S.-domiciled clinical-stage company focused on type 1 diabetes.
• The merged group is expected to pair Seraxis stem cell-derived pancreatic islet programs with Sernova’s implantable, retrievable Cell Pouch delivery platform.
• The combination is slated to close in November 2026, subject to customary closing conditions and approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sernova Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250700PRIMZONEFULLFEED9833803) on September 25, 2026, and is solely responsible for the information contained therein.